Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives

References

• McCrae K. Immune thrombocytopenia: no longer ‘idiopathic’. Cleve Clin J Med. 2011;78(6):358–373. doi:10.3949/ccjm.78gr.10005
   PubMedGoogle Scholar
• Nuent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146(6):585. doi:10.1111/j.1365-2141.2009.07717.x
   PubMed Web of Science ®Google Scholar
• Toltl LJ, Arnold DM. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol. 2011;152(1):52. doi:10.1111/j.1365-2141.2010.08412.x
   PubMed Web of Science ®Google Scholar
• Onisâi M, Vlădăreanu A-M, Spînu A, Găman M, Bumbea H. Idiopathic thrombocytopenic purpura (ITP) – new era for an old disease. Rom J Intern Med. 2019;57(4):273–283.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386. doi:10.1182/blood-2008-07-162503
   PubMed Web of Science ®Google Scholar
• Zufferey A, Kapur R, Semple J. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). JCM. 2017;6(2):16. doi:10.3390/jcm6020016
   Web of Science ®Google Scholar
• Samson M, Fraser W, Lebowitz D. Treatments for primary immune thrombocytopenia: a review. Cureus. 2019;11(10):e5849. doi:10.7759/cureus.5849
   PubMed Web of Science ®Google Scholar
• Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174–180. doi:10.1002/ajh.21616
   PubMed Web of Science ®Google Scholar
• Zeller B, Rajantie J, Hedlund-Treutiger I, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease: childhood ITP in the Nordic countries. Acta Paediatrica. 2007;94(2):178–184. doi:10.1111/j.1651-2227.2005.tb01887.x
   Web of Science ®Google Scholar
• Terrell DR, Beebe LA, Neas BR, Vesely SK, Segal JB, George JN. Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol. 2012;87(9):848–852. doi:10.1002/ajh.23262
   PubMed Web of Science ®Google Scholar
• Despotovic JM, Grimes AB. Pediatric ITP: is it different from adult ITP? Hematology Am Soc Hematol Educ Program. 2018;2018(1):405–411. doi:10.1182/asheducation-2018.1.405
   PubMed Web of Science ®Google Scholar
• Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96(2):188–198. doi:10.1002/ajh.26045
   PubMed Web of Science ®Google Scholar
• Kuhne T, Berchtold W, Michaels LA, et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica. 2011;96(12):1831–1837. doi:10.3324/haematol.2011.050799
   PubMed Web of Science ®Google Scholar
• Charrot SC, Sellar RS, Manson JJ. Purpura. Br J Hosp Med. 2017;78(10):C147–C151. doi:10.12968/hmed.2017.78.10.C147
   Web of Science ®Google Scholar
• Mithoowani S, Cervi A, Shah N, et al. Management of major bleeds in patients with immune thrombocytopenia. J Thromb Haemost. 2020;18(7):1783. doi:10.1111/jth.14809
   PubMed Web of Science ®Google Scholar
• Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2015;13(3):457–464. doi:10.1111/jth.12813
   PubMed Web of Science ®Google Scholar
• Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom general practice research database. Haematologica. 2010;95(7):1167–1175. doi:10.3324/haematol.2009.018390
   PubMed Web of Science ®Google Scholar
• Nørgaard M, Severinsen MT, Lund Maegbaek M, Jensen AØ, Cha S, Sørensen HT. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2012;159(1):109. doi:10.1111/j.1365-2141.2012.09231.x
   PubMed Web of Science ®Google Scholar
• Nørgaard M, Cetin K, Maegbaek ML, et al. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study. Br J Haematol. 2016;174(4):639. doi:10.1111/bjh.13787
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Maegbaek ML, Nørgaard M. Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2014;166(2):260–267. doi:10.1111/bjh.12869
   PubMed Web of Science ®Google Scholar
• Care A, Pavord S, Knight M, Alfirevic Z. Severe primary autoimmune thrombocytopenia in pregnancy: a national cohort study. BJOG. 2018;125(5):604–612. doi:10.1111/1471-0528.14697
   PubMed Web of Science ®Google Scholar
• Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829–2835. doi:10.1182/blood-2017-03-754119
   PubMed Web of Science ®Google Scholar
• Bomhof G, Mutsaers PGNJ, Leebeek FWG, et al. COVID‐19‐associated immune thrombocytopenia. Br J Haematol. 2020;190(2). doi:10.1111/bjh.16850
   PubMed Web of Science ®Google Scholar
• Murt A, Eskazan AE, Yılmaz U, Ozkan T, Ar MC. COVID‐19 presenting with immune thrombocytopenia: a case report and review of the literature. J Med Virol. 2021;93(1):43–45. doi:10.1002/jmv.26138
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Compr Clin Med. 2020;2(11):2048–2058. doi:10.1007/s42399-020-00521-8
   PubMedGoogle Scholar
• Sahu KK, Siddiqui AD, Rezaei N, Cerny J. Challenges for management of immune thrombocytopenia during COVID‐19 pandemic. J Med Virol. 2020;92(11):2277–2282. doi:10.1002/jmv.26251
   PubMed Web of Science ®Google Scholar
• Mahévas M, Moulis G, Andres E, et al. Clinical characteristics, management and outcome of COVID‐19‐associated immune thrombocytopenia: a French multicentre series. Br J Haematol. 2020;190(4). doi:10.1111/bjh.17024
   PubMed Web of Science ®Google Scholar
• Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145–148. doi:10.1016/j.cca.2020.03.022
   PubMed Web of Science ®Google Scholar
• Vayne C, Guery E, Rollin J, Baglo T, Petermann R, Gruel Y. Pathophysiology and diagnosis of drug-induced immune thrombocytopenia. J Clin Med. 2020;9(7):2212. doi:10.3390/jcm9072212
   PubMed Web of Science ®Google Scholar
• Arnold DM, Cuker A. Immune thrombocytopenia (ITP) in adults: clinical manifestations and diagnosis. UpToDate. Available from: https://www.uptodate.com/contents/immune-thrombocytopenia-itp-in-adults-clinical-manifestations-and-diagnosis?search=immune%20thrombocytopenia&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H21. Accessed October 22, 2021.
   Google Scholar
• Tintinalli JE. Tintinalli’s Emergency Medicine. 8th ed. McGraw-Hill Companies; 2015:1491.
   Google Scholar
• Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286. doi:10.1056/NEJM200104263441704
   PubMed Web of Science ®Google Scholar
• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995. doi:10.1056/NEJMra010501
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207. doi:10.1182/blood-2010-08-302984
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168. doi:10.1182/blood-2009-06-225565
   PubMed Web of Science ®Google Scholar
• Davoren A, Bussel J, Curtis BR, Moghaddam M, Aster RH, McFarland JG. Prospective evaluation of a new platelet glycoprotein (GP)-specific assay (PakAuto) in the diagnosis of autoimmune thrombocytopenia (AITP). Am J Hematol. 2005;78(3):193–197. doi:10.1002/ajh.20309
   PubMed Web of Science ®Google Scholar
• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829. doi:10.1182/bloodadvances.2019000966
   PubMed Web of Science ®Google Scholar
• Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780. doi:10.1182/bloodadvances.2019000812
   PubMed Web of Science ®Google Scholar
• Sirotich E, Guyatt G, Gabe C, et al. Definition of a critical bleed in patients with immune thrombocytopenia: communication from the ISTH SSC subcommittee on platelet immunology. J Thromb Haemost. 2021;19:2082. doi:10.1111/jth.15368
   PubMed Web of Science ®Google Scholar
• McCullough J. Overview of platelet transfusion. Semin Hematol. 2010;47(3):235–242. doi:10.1053/j.seminhematol.2010.04.001
   PubMed Web of Science ®Google Scholar
• Baumann MA, Menitove JE, Aster RH, Anderson T. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Intern Med. 1986;104:808. doi:10.7326/0003-4819-104-6-808
   PubMed Web of Science ®Google Scholar
• Praituan W, Rojnuckarin P. Faster platelet recovery by high-dose dexamethasone compared with standard-dose prednisolone in adult immune thrombocytopenia: a prospective randomized trial. J Thromb Haemost. 2009;7(6):1036–1038. doi:10.1111/j.1538-7836.2009.03359.x
   PubMed Web of Science ®Google Scholar
• Mithoowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2016;3(10):e489. doi:10.1016/S2352-3026(16)30109-0
   PubMed Web of Science ®Google Scholar
• Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet. 2002;359(9300):23. doi:10.1016/S0140-6736(02)07275-6
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Bussel JB, Cines DB, et al. A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Blood. 2007;109:5527; author reply 5528. doi:10.1182/blood-2006-03-004481
   PubMed Web of Science ®Google Scholar
• Gaines AR. Response: further examination of intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Blood. 2007;109:5528. doi:10.1182/blood-2007-02-070706
   PubMed Web of Science ®Google Scholar
• Garratty G. What is the mechanism for acute hemolysis occurring in some patients after intravenous anti-D therapy for immune thrombocytopenic purpura? Transfusion. 2009;49:1026.
   PubMed Web of Science ®Google Scholar
• Mayer B, Salama A. Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia. Vox Sang. 2017;112(8):767–772. doi:10.1111/vox.12549
   PubMed Web of Science ®Google Scholar
• Gernsheimer TB, Brown SP, Triulzi DJ, et al. Effects of tranexamic acid prophylaxis on bleeding outcomes in hematologic malignancy: the a-TREAT trial. Blood. 2020;136(1):1–2. doi:10.1182/blood-2020-138920
   PubMed Web of Science ®Google Scholar
• Gottlieb M, DeMott JM, Peksa GD. Topical tranexamic acid for the treatment of acute epistaxis: a systematic review and meta-analysis. Ann Pharmacother. 2019;53(6):652. doi:10.1177/1060028018820625
   PubMed Web of Science ®Google Scholar
• Gardner FH, Helmer RE 3rd. Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA. 1980;243(1):35. doi:10.1001/jama.1980.03300270023023
   PubMed Web of Science ®Google Scholar
• Bartholomew JR, Salgia R, Bell WR. Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med. 1989;149(9):1959. doi:10.1001/archinte.1989.00390090039008
   PubMedGoogle Scholar
• Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer. 2006;107(1):13. doi:10.1002/cncr.21958
   Web of Science ®Google Scholar
• Giordano P, Lassandro G, Barone A, et al. Use of eltrombopag in children with chronic immune thrombocytopenia (ITP): a real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Front Med. 2020;7:66. doi:10.3389/fmed.2020.00066
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Pell J, Hill Q, et al. Mycophenolate Mofetil for first-line treatment of immune thrombocytopenia. N Engl J Med. 2021;385:885–895. doi:10.1056/NEJMoa2100596
   PubMed Web of Science ®Google Scholar